China Investments and Licensing Deals

Image: iStock/Golden_Brown

This webcast features: Dr. Linda Pullan, Founder, Pullan Consulting

China’s biopharmaceutical industry is continuing its growth momentum. This robust growth is boosted by continuous investment into the sector. A clear strategic indicator of the government’s intentions in biopharma and biologics has been the China’s investment in biopharma industrial hubs, which will have added more than USD $300 billion to the biological industry nationwide by 2020. In Part 2 of our series, Dr. Linda Pullan, Principal, Pullan Consulting, covers China investments, as well as advice for negotiating China deals.

Watch the recorded webcast below.